Variants in BAG3 and Cardiomyopathy Outcomes in African Americans
Study Questions:
Is the BAG3 genetic variant associated with nonischemic dilated cardiomyopathy (DCM) outcomes among individuals with African ancestry?
Methods:
DNA was analyzed from African American individuals enrolled in three clinical studies: GRAHF (Genetic Risk Assessment of African Americans With Heart Failure), IMAC-2 (Intervention in Myocarditis and Acute Cardiomyopathy Trial-2), and GRACE (Genetic Risk Assessment of Cardiac Events), as well as those undergoing heart transplantation at the University of Colorado and University of Pittsburgh. The prevalence of BAG3 mutations and event-free survival in participants with functional BAG3 mutations were assessed.
Results:
There were four BAG3 genetic variants identified. Among African American individuals, the BAG3 variants were expressed in 42/402 (10.4%) with nonischemic DCM and 9/107 (8.4%) with ischemic heart failure; however, these variants were not present in a reference group of European ancestry (p < 0.001). Carriers of BAG3 variants had a nearly twofold increase (hazard ratio, 1.97; 95% confidence interval, 1.19-3.24; p = 0.01) in cardiac events (death, transplant, or heart failure-associated hospitalizations).
Conclusions:
Genetic variants in BAG3 were present almost exclusively in individuals of African ancestry. These variants were not causative of disease, but were associated with increased risk of adverse outcomes in patients with heart failure.
Perspective:
The four genetic variants identified in this study are also present among individuals of African ancestry without known cardiovascular disease. Thus, these variants, which have previously been labeled as benign or indeterminate mutations, are not causative of disease. However, these variants were associated with worse combined outcomes in heart failure. Several important issues are raised: 1) There are complex interactions between genetic modifiers and other biological and environmental factors that may contribute to disease manifestation. 2) The presence of these genetic variants among individuals with African ancestry but not among individuals with European ancestry highlights the importance of conducting genetic studies in racially/ethnically diverse populations. 3) Future studies of genetic variants that may modify the outcomes of various disease processes are necessary. From a clinical standpoint, it remains unclear whether the detection of such a genetic variant should in some way influence the type of treatment or counseling given to an individual. There is still much to learn about the genetic basis of heart failure, but it is clearly essential to conduct these studies in diverse populations.
Clinical Topics: Cardiac Surgery, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Cardiac Surgery and Heart Failure, Acute Heart Failure, Heart Transplant
Keywords: African Americans, Cardiomyopathies, Cardiomyopathy, Dilated, Genetic Variation, Heart Failure, Heart Transplantation, Heterozygote, Mutation, Myocarditis, Risk Assessment
< Back to Listings